Tech's relief rally extends as attention turns to tough decisions for the Fed

Optimism around Anthropic’s planned Nasdaq IPO next month supported technology stocks for a second day, though its S-1 filing describes governance that gives everyday shareholders little voice. Markets priced a 90% chance of a December Fed hike ahead of an expected hawkish hold this week. Company updates were mixed: Coca-Cola raised its earnings outlook for a third consecutive quarter despite weaker North American demand, Novartis lifted its profit outlook, and HSBC shares fell after results missed expectations and guidance was conservative. Microsoft is offering voluntary buyouts to eligible employees, with about 60,000 people—roughly 27% of its 223,000-person workforce—eligible.

Analysis

The key market tension is AI demand validation versus the cost of supplying it. Anthropic’s IPO can briefly lift AI multiples, but public disclosure and founder-heavy governance may also force investors to distinguish commercial traction from capital intensity and shareholder rights. Treat the rally as sentiment-sensitive until filings clarify revenue quality, cash burn, and infrastructure commitments; an IPO timetable is not evidence of sector-wide returns on capex.

For Microsoft, the buyout offer is not yet a headcount or savings forecast: uptake, severance expense, role mix, and whether savings are redeployed to AI infrastructure matter more than eligibility. Over 1–3 months, evidence of lower operating expense without slower product execution would support the efficiency thesis; unusually high uptake in critical teams or continued capex acceleration without monetization would undermine it. The broader risk is that higher-for-longer rates raise the hurdle rate on long-dated AI cash flows. With a December hike already heavily priced, the asymmetry is less attractive for a fresh front-end short absent a more hawkish signal.

Earnings dispersion matters more than the broad headline: HSBC’s guidance miss challenges the assumption that higher rates automatically translate into earnings upside, while Novartis’s upgraded outlook still needs to be tested against patent-loss exposure. Coca-Cola’s repeated guidance increases are supportive, but weaker North American demand and substantial year-to-date outperformance leave less room for disappointment. Boeing’s narrower loss is not proof that production stabilization is on schedule. The contrarian risk is chasing AI enthusiasm while ignoring the cost of capital and execution; conversely, a softer Fed signal or credible evidence of AI monetization could extend the rally.

Key Decisions for Investors

• Do not chase a second-day AI rally on IPO enthusiasm alone. Track Anthropic’s S-1 for revenue concentration, cash burn, capex commitments, and governance terms; deteriorating unit economics would be a falsifier for the sentiment-led re-rating.
• Keep a conditional Nasdaq-100 put spread on the watchlist as a defined-risk hedge, entering only if front-end yields move higher after the Fed communication and high-duration technology weakens. If the Fed signals less tightening than priced and yields ease, stand down rather than pay for a hedge into relief.
• Treat Microsoft’s buyout program as an execution monitor, not an immediate margin catalyst. Verify actual participation, one-time costs, subsequent workforce expense, and AI capex guidance; rising spend without improving monetization or productivity would weaken the efficiency thesis.
• Avoid adding to Coca-Cola after its outperformance until demand and pricing/mix support the raised outlook; a guidance cut or further North American demand deterioration would be a catalyst to reassess. For Boeing, require evidence that production stabilization is on track before treating a narrower quarterly loss as a durable turn.